Cargando…
Response to Letter to the Editor Regarding: Indirect Treatment Comparison of Inotuzumab Ozogamicin versus Blinatumomab for Relapsed or Refractory Acute Lymphoblastic Leukemia
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer Healthcare
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7004421/ https://www.ncbi.nlm.nih.gov/pubmed/31838711 http://dx.doi.org/10.1007/s12325-019-01169-0 |
| _version_ | 1783494720184385536 |
|---|---|
| author | Proskorovsky, Irina Vandendries, Erik Pagé, Véronique Cappelleri, Joseph C. Stelljes, Matthias |
| author_facet | Proskorovsky, Irina Vandendries, Erik Pagé, Véronique Cappelleri, Joseph C. Stelljes, Matthias |
| author_sort | Proskorovsky, Irina |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-7004421 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2019 |
| publisher | Springer Healthcare |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-70044212020-02-25 Response to Letter to the Editor Regarding: Indirect Treatment Comparison of Inotuzumab Ozogamicin versus Blinatumomab for Relapsed or Refractory Acute Lymphoblastic Leukemia Proskorovsky, Irina Vandendries, Erik Pagé, Véronique Cappelleri, Joseph C. Stelljes, Matthias Adv Ther Letter Springer Healthcare 2019-12-14 2020 /pmc/articles/PMC7004421/ /pubmed/31838711 http://dx.doi.org/10.1007/s12325-019-01169-0 Text en © The Author(s) 2019 Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/. |
| spellingShingle | Letter Proskorovsky, Irina Vandendries, Erik Pagé, Véronique Cappelleri, Joseph C. Stelljes, Matthias Response to Letter to the Editor Regarding: Indirect Treatment Comparison of Inotuzumab Ozogamicin versus Blinatumomab for Relapsed or Refractory Acute Lymphoblastic Leukemia |
| title | Response to Letter to the Editor Regarding: Indirect Treatment Comparison of Inotuzumab Ozogamicin versus Blinatumomab for Relapsed or Refractory Acute Lymphoblastic Leukemia |
| title_full | Response to Letter to the Editor Regarding: Indirect Treatment Comparison of Inotuzumab Ozogamicin versus Blinatumomab for Relapsed or Refractory Acute Lymphoblastic Leukemia |
| title_fullStr | Response to Letter to the Editor Regarding: Indirect Treatment Comparison of Inotuzumab Ozogamicin versus Blinatumomab for Relapsed or Refractory Acute Lymphoblastic Leukemia |
| title_full_unstemmed | Response to Letter to the Editor Regarding: Indirect Treatment Comparison of Inotuzumab Ozogamicin versus Blinatumomab for Relapsed or Refractory Acute Lymphoblastic Leukemia |
| title_short | Response to Letter to the Editor Regarding: Indirect Treatment Comparison of Inotuzumab Ozogamicin versus Blinatumomab for Relapsed or Refractory Acute Lymphoblastic Leukemia |
| title_sort | response to letter to the editor regarding: indirect treatment comparison of inotuzumab ozogamicin versus blinatumomab for relapsed or refractory acute lymphoblastic leukemia |
| topic | Letter |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7004421/ https://www.ncbi.nlm.nih.gov/pubmed/31838711 http://dx.doi.org/10.1007/s12325-019-01169-0 |
| work_keys_str_mv | AT proskorovskyirina responsetolettertotheeditorregardingindirecttreatmentcomparisonofinotuzumabozogamicinversusblinatumomabforrelapsedorrefractoryacutelymphoblasticleukemia AT vandendrieserik responsetolettertotheeditorregardingindirecttreatmentcomparisonofinotuzumabozogamicinversusblinatumomabforrelapsedorrefractoryacutelymphoblasticleukemia AT pageveronique responsetolettertotheeditorregardingindirecttreatmentcomparisonofinotuzumabozogamicinversusblinatumomabforrelapsedorrefractoryacutelymphoblasticleukemia AT cappellerijosephc responsetolettertotheeditorregardingindirecttreatmentcomparisonofinotuzumabozogamicinversusblinatumomabforrelapsedorrefractoryacutelymphoblasticleukemia AT stelljesmatthias responsetolettertotheeditorregardingindirecttreatmentcomparisonofinotuzumabozogamicinversusblinatumomabforrelapsedorrefractoryacutelymphoblasticleukemia |